Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Colonic Botulinum Toxin vs Placebo After Restorative TME for Rectal Cancer
2025-524342-96-00Phase 2Authorised
- Sponsor
- UZ Leuven
- Start
- Apr 2026
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in rectal cancer comparing Botox with Placebo (2 arms). Primary endpoint: Difference in LARS score between Botox and placebo groups at 3 months. Planned start Apr 2026; status: authorised.
02
Drugs
botulinum toxin type A
03
Conditions
rectal cancer
Beyond the preview
Go deeper on 2025-524342-96-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-524342-96-00.